These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 16985239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z.
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract] [Full Text] [Related]

  • 4. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM.
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J, Johnson M, Seidman A.
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [Abstract] [Full Text] [Related]

  • 7. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
    Pritchard KI.
    J Clin Oncol; 2005 Aug 01; 23(22):4850-2. PubMed ID: 16009956
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF, Manikhas AG, Semiglazov VV, Bozhok AA, Dashian GA, Ivanov VG, Paltuev RM, Vasil'ev AG, Shchedrin DE, Ermachenkova AM, Nikitina IV, Pen'kov KD, Bessonov AA, Tabagua TT, Kolar'kova VV.
    Vopr Onkol; 2011 Aug 01; 57(5):567-77. PubMed ID: 22238925
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
    Tuma RS.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):86-7. PubMed ID: 16418506
    [No Abstract] [Full Text] [Related]

  • 13. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J, Agrawal A, Asgeirsson KS, Buhari SA, Jackson LR, Cheung KL, Robertson JF.
    Breast Cancer Res Treat; 2009 Jan 18; 113(2):403-7. PubMed ID: 18311583
    [Abstract] [Full Text] [Related]

  • 14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Jan 18; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A, Buyse M.
    J Clin Oncol; 2002 Apr 01; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant endocrine therapy for breast cancer: don't ditch the switch!
    Puhalla S, Jankowitz RC, Davidson NE.
    J Natl Cancer Inst; 2011 Sep 07; 103(17):1280-2. PubMed ID: 21859987
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.